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Some new hybrid 2-aryl-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-benzo[b][1,4]diazepines have been 
synthesised which possessed the pyrazole and benzodiazepine heterocycles 2a-t. Antimicrobial evaluation of the synthesized 
compounds have been carried out against different strains of bacteria like E. coli, P. aeruginosa, S. aureus and S. pyogenes 
and fungal strains like C. albicans, A. niger and A. clavatus using serial dilution method. The newly synthesized compounds 
2i, 2j, 2k, 2l, 2m, 2q and 2t have shown significant activity against the above mentioned strains. The reported compounds in 
the present paper are supported by IR, 1H and 13C NMR, and LC-MS spectral analysis. 
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Though many pharmaceutical drugs have been used 
on bacteria and fungi available in the market, 
microbial infection is a rising global problem due to 
the resistance of present antimicrobials1,2. We have 
observed the increasing level of microbial diseases in 
the surrounding geographical area too3,4. The only 
solution is to find new antimicrobials having zero 
resistance on microbes. Keeping this in mind, we 
have synthesized a new diverse structure of molecules 
for fighting against microbial infections based on 
heterocyclic chemistry. The literature review 
suggested that heterocyclic compounds have very 
good pharmacological effects5-8. Recently some 
review articles were published and on the basis of 
these articles, it is concluded that pyrazole9-11 and 
benzodiazepine12-15 showed notable pharmaceutical 
efficacy and therefore we have selected these versatile 
motifs in the present work. We have used a hybrid 
approach, using pyrazole and benzodiazepine in the 
same structure. Certain commercially available 
medicines are also having pyrazole and 
benzodiazepine motif. Some of them are shown in 
Figure 1 below. 
 
Results and Discussion 
Chemistry 
The development of non-hazardous synthetic 
methodologies for organic reactions is one of the most 
complicated issues to the organic chemists now a 
days. In continuation to this, we synthesized 2-aryl-4-
(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-2,3-dihydro-
1H-benzo[b][1,4]diazepines (2a-t) by a one-pot 
synthesis with the use of 1-phenyl-3-(1-phenyl-3- 
(p-tolyl)-1H-pyrazol-4-yl)prop-2-en-1-ones  (1a-t) 
and benzene-1,2-diamine (Scheme I). This simple 
reaction was carried out in the presence of catalysts 
i.e. piperidine and acetic acid. 0.01 mol of chalcones  
(1a-t) was added to DMF, after the dissolution of  
(1a-t) benzene-1,2-diamine was added in the double 
ratio. The reaction was refluxed for 8-10 h for 
completion. 
 
Antimicrobial Assay 
“Antimicrobial activity was accomplished by 
Mueller Hinton Broth dilution method (Becton 
Dickinson, USA)16,. The strains were acquired from 
the IMTECH, Chandigarh, India. Antibacterial 
activity was screened in triple sets at diverse 
concentrations of 1000, 500, 250 and 200 µg/mL. The 
compounds which were found to be active in primary 
analysis were further diluted and evaluated. 10 µg/mL 
suspensions were further injected on appropriate 
media and the growth was noted after one or two 
days. In antifungal evaluation, primary screening was 
carried out in six sets at different concentrations of 
1000, 500, and  250 µg/mL.  The  compounds  found  
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Figure 1 — Commercially available drug candidates containing pyrazole and benzodiazepine 
 
 
 
Scheme I — Synthetic pathway of the reported compounds 2a-t 
 
active were similarly diluted to 200, 125, 100,  
62.5, 50, 25, and 12.5 µg/mL concentrations for  
a secondary screening. Minimum Inhibitory 
Concentration (MIC) is the lowest concentration 
which showed no growth of microbes after spot 
subculture for each compound. In this study, 
Ciprofloxacin and Nystatin were the standard drugs 
for evaluating the antibacterial activity and antifungal 
activity respectively.” 17 
 
Discussion on antimicrobial activity 
Antimicrobial activity data are as shown in Table I. 
A few compounds showed a minimum inhibitory 
concentration (MIC) value less than the standard 
drug, while some compounds showed values 
comparable to the standard drug. The most active 
compound among the twenty derivatives is 2q (-2,4-
Cl2) which showed 12.5 µg/mL MIC value against 
E.coli. Compounds 2m and 2j showed significant 
activity as compared to standard drug (Ciprofloxacin) 
for S. aureus and S. pyogenes strains of fungi 
respectively. Compounds 2l (-4-CH3) and 2k (-4-
OCH3) showed very good activity against C. albicans. 
Compound 2t (-4-OH-3-OCH3) showed prominent 
activity against A. niger while compound 2i exhibited 
similar potency to standard drug (Nystatin) for A. 
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niger and A. clavatus strains of fungi.The Standard 
drug used was Ciprofloxacin and Nystatin for 
antibacterial and antifungal activity respectively. 
 
Experimental Section 
Synthesis of 1-phenyl-3-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)prop-2-en-1-one, 1a-t was achieved by 
the literature procedure18. 
 
Synthesis of 2-phenyl-4-(1-phenyl-3-(p-tolyl)- 1H- 
pyrazol-4-yl)-2,3-dihydro-1Hbenzo[b][1,4]diazepines, 
2a-t 
Compounds 1a-t (0.01 mol), benzene-1,2-diamine 
(0.02 mol) in DMF (10 mL) were taken in a round 
bottom flask and refluxed for 8-10 h. Piperidine and 
glacial acetic acid were used as catalysts in the 
reaction mixture. This reaction mixture was poured 
into crushed ice to give the product which was filtered 
and washed with ethyl acetate (to remove any traces 
of chalcone), followed by hot water (to remove an 
excess of OPD) and then recrystallization from 
ethanol (95%). 
Physical constants and characterization of 2-
phenyl-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-
2,3-dihydro-1H-benzo[b][1,4]diazepine, 2a: IR 
(KBr): 680 (-C-H bending, aromatic ring), 740, 752  
(-C-H bending, 1,2-substituted ring 
(benzodiazepine)), 811 (-C-H bending, 1,4-substituted 
benzene ring), 962 (-C-H bending, aromatic ring), 
1294 (-C-N stretching, pyrazole ring (>N-H)), 1396  
(-C-H bending, -CH3 group), 1474 (-C-H bending, 
aromatic ring), 1516, 1574 (-N-H bending, 
benzodiazepine ring (>N-H)) cm−1; 1H NMR (400 
MHz, CDCl3): δ 2.32 (s, 3H, -CH3), 2.52 (dd, J = 5.7, 
1.9 Hz, 1H, H-C-H of benzodiazepine), 2.78 (dd,  
J = 5.7, 2.1 Hz, 1H, H-C-H of benzodiazepine), 3.91 
(s, 1H, -CH of benzodiazepine), 5.86 (s, 1H, -NH of 
benzodiazepine), 6.86-7.67 (m, 18H, Ar-H), 8.43  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.4, 39.5, 64.4, 112.9, 114.5, 119.7 (2), 
121.8, 126.3, 126.7, 126.8, 127.0 (2), 128.2, 128.5 
(2), 128.8 (2), 129.4 (2), 129.6 (2), 130.2, 130.5, 
131.8, 137.4, 139.8, 140.5, 145.6, 150.2, 162.8; LC-
Table I — Results of biological activities of compounds 2a-t 
Compd -R 
Minimum bactericidal concentrations 
(MICB) in µg/mL 
Minimum fungicidal concentrations 
(MICF) in µg/mL 
E. c. P. a. S. a. S. p. C. a. A. n. A. c. 
2a -H 100 125 200 250 250 500 500 
2b -3-NO2 125 50 125 200 1000 250 250 
2c -4-NO2 62.5 100 125 100 1000 1000 250 
2d -3-Br 100 250 100 100 500 1000 500 
2e -4-Br 250 125 62.5 100 1000 500 250 
2f -2-OH 100 100 100 125 >1000 250 500 
2g -3-OH 250 250 200 250 >1000 >1000 >1000 
2h -4-OH 62.5 100 62.5 100 500 1000 1000 
2i -2-OCH3 50 250 100 250 250 100 100 
2j -3-OCH3 100 200 62.5 50 100 50 500 
2k -4-OCH3 200 250 100 100 50 1000 1000 
2l -4-CH3 250 200 62.5 100 25 500 200 
2m -2-Cl 100 100 50 125 250 >1000 1000 
2n -4-Cl 125 62.5 100 200 500 >1000 >1000 
2o -4-F 100 250 125 250 1000 500 1000 
2p -2,4-F2 200 250 250 250 >1000 500 >1000 
2q -2,4-Cl2 12.5 200 250 100 1000 >1000 >1000 
2r -3,4-Cl2 250 100 125 250 500 200 250 
2s -2-Br-4-Cl 62.5 200 200 100 500 250 250 
2t -4-OH-3-OCH3 125 100 250 100 1000 25 250 
Ciprofloxacin 25 25 50 50 ─ ─ ─ 
Nystatin ─ ─ ─ ─ 100 100 100 
Escherichia coli (E.c.) MTCC-442; Pseudomonas aeruginosa (P.a.) MTCC-441. 
Staphylococcus aureus (S.a.) MTCC-96; Streptococcus pyogenes (S.p.) MTCC-443. 
Candida albicans (C.a.) MTCC-227; Aspergillus niger(A.n.) MTCC-282; Aspergillus clavatus (A.c.) MTCC-1323. 
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MS: m/z 454.31 [M+]. Anal. Calcd for: C31H26N4: C, 
81.91; H, 5.77; N, 12.33. Found: C, 81.90; H, 5.75;  
N, 12.34%. 
Physical constants and characterization of 2-(3-
nitrophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-
yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2b: IR 
(KBr): 678 (-C-H bending, aromatic ring), 754 (-C-H 
bending, 1,2-substituted ring (benzodiazepine)), 825 
(-C-H bending, 1,4-substituted benzene ring), 974  
(-C-H bending, aromatic ring), 1305 (-C-N stretching, 
pyrazole ring (>N-H)), 1378 (-C-H bending, -CH3 
group), 1456 (-C-H bending, aromatic ring), 1347, 
1512 (-N=O stretching, -NO2 group), 1524, 1582 (-N-
H bending, benzodiazepine ring (>N-H)) cm−1; 
1H NMR (400 MHz, CDCl3): δ 2.35 (s, 3H, -CH3), 
2.51 (dd, J = 5.7, 1.1 Hz, 1H, H-C-H of 
benzodiazepine), 2.78 (dd, J = 5.3, 1.8 Hz, 1H, H-C-H 
of benzodiazepine), 3.93 (s, 1H, -CH of 
benzodiazepine), 5.89 (s, 1H, -NH of 
benzodiazepine), 6.90-8.24 (m, 17H, Ar-H), 8.43  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.3, 39.1, 62.3, 113.2, 114.7, 119.8 (2), 
120.4, 121.7, 121.9, 126.2, 126.7, 128.3, 128.6 (2), 
129.2, 129.5 (2), 129.6 (2), 130.1, 130.6, 131.6, 
133.2, 137.5, 139.9, 144.2, 145.3, 147.5, 150.3, 162.7; 
LC-MS: m/z 499.59[M+]. Anal. Calcd for: 
C31H25N5O2: C, 74.53; H, 5.04; N, 14.02. Found: C, 
74.55; H, 5.02; N, 14.00%. 
Physical constants and characterization of 2-(4-
nitrophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-
yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2c: IR 
(KBr): 684 (-C-H bending, aromatic ring), 742, 757  
(-C-H bending, 1,2-substituted ring 
(benzodiazepine)), 816 (-C-H bending, 1,4-substituted 
benzene ring), 963 (-C-H bending, aromatic ring), 
1344 (-C-N stretching, pyrazole ring (>N-H)), 1365  
(-C-H bending, -CH3 group), 1463 (-C-H bending, 
aromatic ring), 1351, 1537 (-N=O stretching, -NO2 
group), 1526, 1574 (-N-H bending, benzodiazepine 
ring (>N-H)) cm−1; 1H NMR (400 MHz, CDCl3):  
δ 2.30 (s, 3H, -CH3), 2.52 (dd, J = 7.2, 6.0 Hz, 1H,  
H-C-H of benzodiazepine), 2.76 (dd, J = 8.3, 7.1 Hz, 
1H, H-C-H of benzodiazepine), 3.92 (s, 1H, -CH of 
benzodiazepine), 5.90 (s, 1H, -NH of 
benzodiazepine), 6.84-8.15 (m, 17H, Ar-H), 8.43  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.4, 39.2, 63.2, 113.3, 114.5, 119.9 (2), 
121.6, 123.5 (2), 123.9 (2), 126.3, 126.8, 128.2, 128.5 
(2), 129.6 (2), 129.7 (2), 130.2, 130.5, 131.7, 137.4, 
139.8, 145.2, 145.8, 146.8, 150.4, 162.6; LC-MS: m/z 
499.53 [M+]. Anal. Calcd for: C31H25N5O2: C, 74.53; 
H, 5.04; N, 14.02. Found: C, 74.54; H, 5.05; N, 
14.03%. 
Physical constants and characterization of 2-(3-
bromophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-
4-yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2d: 
IR (KBr): 512 (-C-Br stretching, -Br group), 680 (-C-
H bending, aromatic ring), 744, 751 (-C-H bending, 
1,2-substituted ring (benzodiazepine)), 824 (-C-H 
bending, 1,4-substituted benzene ring), 971 (-C-H 
bending, aromatic ring), 1324 (-C-N stretching, 
pyrazole ring (>N-H)), 1384 (-C-H bending, -CH3 
group), 1470 (-C-H bending, aromatic ring), 1534, 
1565 (-N-H bending, benzodiazepine ring (>N-H)) 
cm−1; 1H NMR (400 MHz, CDCl3): δ 2.36 (s, 3H, -
CH3), 2.55 (dd, J = 7.2, 5.9 Hz, 1H, H-C-H of 
benzodiazepine), 2.79 (dd, J = 17.0, 2.1 Hz, 1H, H-C-
H of benzodiazepine), 3.94 (s, 1H, -CH of 
benzodiazepine), 5.86 (s, 1H, -NH of 
benzodiazepine), 6.90-7.64 (m, 17H, Ar-H), 8.45  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.2, 39.3, 62.5, 113.1, 114.5, 119.6 (2), 
121.5, 122.4, 125.6, 126.3, 126.6, 128.4, 128.7 (2), 
129.2, 129.4 (2), 129.7, 129.8 (2), 130.3, 130.7, 
131.5, 131.8, 137.6, 139.7, 145.2, 145.4, 150.5, 162.6; 
LC-MS: m/z 532.14 [M+]. Anal. Calcd for: 
C31H25BrN4: C,69.80; H, 4.72; N, 10.50. Found: C, 
69.81; H, 4.70; N, 10.53%. 
Physical constants and characterization of 2-(4-
bromophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-
4-yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2e: IR 
(KBr): 543 (-C-Br stretching, -Br group), 692 (-C-H 
bending, aromatic ring), 742 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 829 (-C-H 
bending, 1,4-substituted benzene ring), 976 (-C-H 
bending, aromatic ring), 1286 (-C-N stretching, 
pyrazole ring (>N-H)), 1372 (-C-H bending, -CH3 
group), 1447 (-C-H bending, aromatic ring), 1512, 
1563 (-N-H bending, benzodiazepine ring (>N-H)) 
cm−1; 1H NMR (400 MHz, CDCl3): δ 2.36 (s, 3H,  
-CH3), 2.53 (dd, J = 8.8, 2.4 Hz, 1H, H-C-H of 
benzodiazepine), 2.74 (dd, J = 9.3, 2.4 Hz, 1H, H-C-H 
of benzodiazepine), 3.88 (s, 1H, -CH of 
benzodiazepine), 5.89 (s, 1H, -NH of 
benzodiazepine), 6.85-7.88 (m, 17H, Ar-H), 8.41  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.5, 39.0, 62.9, 113.3, 114.8, 119.7 (2), 
121.3, 121.5, 123.9 (2), 126.3, 126.6, 128.2, 128.5 
(2), 129.5 (2), 129.7 (2), 130.2, 130.4, 131.5, 131.7 
(2), 137.7, 139.4, 139.8, 145.2, 150.2, 162.6; LC-MS: 
m/z 532.16 [M+]. Anal. Calcd for: C31H25BrN4: 
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C,69.80; H, 4.72; N, 10.50. Found: C, 69.81; H, 4.71; 
N, 10.52%. 
Physical constants and characterization of 2-(2-
hydroxyphenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2f: IR (KBr): 687 (-C-H 
bending, aromatic ring), 748, 762 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 823 (-C-H 
bending, 1,4-substituted benzene ring), 982 (-C-H 
bending, aromatic ring), 1316 (-C-N stretching, 
pyrazole ring (>N-H)), 1326 (-C-O-H bending, -OH 
group), 1391 (-C-H bending, -CH3 group), 1471 (-C-H 
bending, aromatic ring), 1522, 1535 (-N-H bending, 
benzodiazepine ring (>N-H)) cm−1; 1H NMR  
(400 MHz, CDCl3): δ 2.33 (s, 3H, -CH3), 2.50 (dd, J = 8.1, 
5.4 Hz, 1H, H-C-H of benzodiazepine), 2.76 (dd,  
J = 17.0, 10.1 Hz, 1H, H-C-H of benzodiazepine), 
3.92 (s, 1H, -CH of benzodiazepine), 5.89 (s, 1H, -NH 
of benzodiazepine), 6.85-7.71 (m, 17H, Ar-H), 8.43 
(s, 1H, -CH of pyrazole), 9.66 (s, 1H, -OH); 13C NMR 
(100 MHz, CDCl3): δ 21.0, 39.4, 56.7, 113.4, 114.6, 
115.8, 119.7 (2), 121.4, 121.5, 126.2, 126.3, 126.7, 
128.0, 128.4, 128.5 (2), 129.7 (2), 129.8 (2), 130.3, 
130.5, 130.7, 131.8, 137.4, 139.7, 145.2, 150.0, 154.2, 
162.6; LC-MS: m/z 470.25 [M+]. Anal. Calcd for: 
C31H26N4O: C, 79.12; H, 5.57; N, 11.91. Found: C, 
79.10; H, 5.56; N, 11.88%. 
Physical constants and characterization of 2-(3-
hydroxyphenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2g: IR (KBr): 690 (-C-H 
bending, aromatic ring), 746, 753 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 817 (-C-H 
bending, 1,4-substituted benzene ring), 959 (-C-H 
bending, aromatic ring), 1316 (-C-O-H bending, -OH 
group), 1327 (-C-N stretching, pyrazole ring (>N-H)), 
1364 (-C-H bending, -CH3 group), 1485 (-C-H 
bending, aromatic ring), 1513, 1575 (-N-H bending, 
benzodiazepine ring (>N-H)) cm−1; 1H NMR (400 
MHz, CDCl3): δ 2.32 (s, 3H, -CH3), 2.56 (dd, J = 5.3, 
1.9 Hz, 1H, H-C-H of benzodiazepine), 2.78 (dd,  
J = 8.7, 5.7 Hz, 1H, H-C-H of benzodiazepine), 3.87 
(s, 1H, -CH of benzodiazepine), 5.84 (s, 1H, -NH of 
benzodiazepine), 6.80-7.70 (m, 17H, Ar-H), 8.45  
(s, 1H, -CH of pyrazole), 9.24 (s, 1H, -OH); 13C NMR 
(100 MHz, CDCl3): δ 21.2, 39.4, 63.4, 112.4, 112.8, 
113.7, 114.6, 119.4, 119.7 (2), 121.5, 126.3, 126.5, 
128.4, 128.7 (2), 129.3 (2), 129.8 (2), 129.9, 130.2, 
130.4, 131.8, 137.4, 139.7, 144.8, 145.2, 150.6, 156.6, 
162.8; LC-MS: m/z 470.24 [M+]. Anal. Calcd for: 
C31H26N4O: C, 79.12; H, 5.57; N, 11.91. Found: C, 
79.13; H, 5.55; N, 11.90%. 
Physical constants and characterization of 2-(4-
hydroxyphenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-benzo[b][1,4] 
diazepine, 2h: IR (KBr): 684 (-C-H bending, 
aromatic ring), 743, 754 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 820 (-C-H 
bending, 1,4-substituted benzene ring), 965 (-C-H 
bending, aromatic ring), 1332 (-C-O-H bending, -OH 
group), 1345 (-C-N stretching, pyrazole ring (>N-H)), 
1387 (-C-H bending, -CH3 group), 1473 (-C-H 
bending, aromatic ring), 1527, 1563 (-N-H bending, 
benzodiazepine ring (>N-H)) cm−1; 1H NMR (400 
MHz, CDCl3): δ 2.35 (s, 3H, -CH3), 2.55 (dd, J = 5.3, 
1.9 Hz, 1H, H-C-H of benzodiazepine), 2.76 (dd,  
J = 8.7, 5.2 Hz, 1H, H-C-H of benzodiazepine), 3.92 
(s, 1H, -CH of benzodiazepine), 5.89 (s, 1H, -NH of 
benzodiazepine), 6.68-7.63 (m, 17H, Ar-H), 8.43  
(s, 1H, -CH of pyrazole), 9.08 (s, 1H, --OH); 
13C NMR (100 MHz, CDCl3): δ 21.1, 39.3, 63.4, 
113.3, 114.6, 115.8 (2), 119.7 (2), 121.5, 126.3, 
126.5, 127.2 (2), 128.4, 128.7 (2), 129.4 (2), 129.5 
(2), 130.2, 130.7, 131.8, 133.2, 137.4, 139.8, 145.2, 
150.1, 156.4, 162.8; LC-MS: m/z 470.20 [M+]. Anal. 
Calcd for: C31H26N4O: C, 79.12; H, 5.57; N, 11.91. 
Found: C, 79.12; H, 5.59; N, 11.90%. 
Physical constants and characterization of 2-(2-
methoxyphenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2i: IR (KBr): 686 (-C-H 
bending, aromatic ring), 752, 760 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 814 (-C-H 
bending, 1,4-substituted benzene ring), 969 (-C-H 
bending, aromatic ring), 1308 (-C-N stretching, 
pyrazole ring (>N-H)), 1365 (-C-H bending, -CH3 
group), 1459 (-C-H bending, aromatic ring), 1534, 
1574 (-N-H bending, benzodiazepine ring (>N-H)), 
2823 (-C-H stretching, -OCH3 group) cm−1; 1H NMR 
(400 MHz, CDCl3): δ 2.36 (s, 3H, -CH3), 2.50 (dd,  
J = 5.4, 51.7 Hz, 1H, H-C-H of benzodiazepine), 2.78 
(dd, J = 9.7, 7.6 Hz, 1H, H-C-H of benzodiazepine), 
3.74 (s, 3H, -OCH3), 3.89 (s, 1H, -CH of 
benzodiazepine), 5.85 (s, 1H, -NH of 
benzodiazepine), 6.87-7.72 (m, 17H, Ar-H), 8.41  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.4, 39.5, 56.2, 57.3, 112.3, 113.4, 114.6, 
119.9 (2), 120.7, 121.5, 126.1, 126.3, 126.4, 127.5, 
128.6, 128.8 (2), 129.2, 129.4 (2), 129.7 (2), 130.2, 
130.7, 131.8, 137.3, 139.6, 145.5, 150.2, 156.4, 162.8; 
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LC-MS: m/z 484.21 [M+]. Anal. Calcd for: 
C32H28N4O: C, 79.31; H, 5.82; N, 11.56. Found: C, 
79.30; H, 5.80; N, 11.58%. 
Physical constants and characterization of 2-(3-
methoxyphenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2j: IR (KBr): 696 (-C-H 
bending, aromatic ring), 741, 752 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 825 (-C-H 
bending, 1,4-substituted benzene ring), 973 (-C-H 
bending, aromatic ring), 1336 (-C-N stretching, 
pyrazole ring (>N-H)), 1382 (-C-H bending, -CH3 
group), 1467 (-C-H bending, aromatic ring), 1518, 
1553 (-N-H bending, benzodiazepine ring (>N-H)), 
2819 (-C-H stretching, -OCH3 group) cm−1; 1H NMR 
(400 MHz, CDCl3): δ 2.31 (s, 3H, -CH3), 2.54 (dd,  
J = 5.3, 1.8 Hz, 1H, H-C-H of benzodiazepine), 2.77 
(dd, J = 8.5, 5.2 Hz, 1H, H-C-H of benzodiazepine), 
3.68 (s, 3H, -OCH3), 3.92 (s, 1H, -CH of 
benzodiazepine), 5.86 (s, 1H, -NH of 
benzodiazepine), 6.86-7.69 (m, 17H, Ar-H), 8.43  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.3, 39.4, 55.6, 63.3, 112.1, 112.5, 113.1, 
114.8, 119.3, 119.9 (2), 121.6, 126.3, 126.8, 128.4, 
128.7 (2), 129.6, 129.6 (2), 129.7 (2), 130.0, 130.7, 
131.7, 137.6, 140.0, 144.3, 145.4, 150.5, 160.5, 162.8;  
LC-MS: m/z 484.24 [M+]. Anal. Calcd for: 
C32H28N4O: C, 79.31; H, 5.82; N, 11.56. Found:  
C, 79.33; H, 5.80; N, 11.53%. 
Physical constants and characterization of 2-(4-
methoxyphenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2k: IR (KBr): 687 (-C-H 
bending, aromatic ring), 750, 758 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 822 (-C-H 
bending, 1,4-substituted benzene ring), 964 (-C-H 
bending, aromatic ring), 1286 (-C-N stretching, 
pyrazole ring (>N-H)), 1390 (-C-H bending, -CH3 
group), 1474 (-C-H bending, aromatic ring), 1541, 
1571 (-N-H bending, benzodiazepine ring (>N-H)), 
2831 (-C-H stretching, -OCH3 group) cm−1; 1H NMR 
(400 MHz, CDCl3): δ 2.32 (s, 3H, -CH3), 2.50 (dd,  
J = 5.4, 1.7 Hz, 1H, H-C-H of benzodiazepine), 2.76 
(dd, J = 16.9, 10.1 Hz, 1H, H-C-H of 
benzodiazepine), 3.82 (s, 3H, -OCH3), 3.93 (s, 1H,  
-CH of benzodiazepine), 5.89 (s, 1H, -NH of 
benzodiazepine), 6.85-7.63 (m, 17H, Ar-H), 8.45  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.0, 39.4, 55.7, 62.9, 113.4, 114.3 (2), 
114.9, 119.6 (2), 121.9, 126.4, 126.6 (2), 126.9, 
128.5, 128.8 (2), 129.7 (2), 129.8 (2), 130.3, 130.7, 
131.8, 132.8, 137.7, 139.6, 145.5, 150.4, 158.4, 162.6; 
LC-MS: m/z 484.22 [M+]. Anal. Calcd for: 
C32H28N4O: C, 79.31; H, 5.82; N, 11.56. Found:  
C, 79.29; H, 5.83; N, 11.55%. 
Physical constants and characterization of 2-(4-
methylphenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-
4-yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2l: IR 
(KBr): 674 (-C-H bending, aromatic ring), 747, 759  
(-C-H bending, 1,2-substituted ring 
(benzodiazepine)), 827 (-C-H bending, 1,4-substituted 
benzene ring), 980 (-C-H bending, aromatic ring), 
1314 (-C-N stretching, pyrazole ring (>N-H)), 1328  
(-C-H bending, -CH3 group), 1378 (-C-H bending,  
-CH3 group), 1460 (-C-H bending, aromatic ring), 
1526, 1579 (-N-H bending, benzodiazepine ring (>N-
H)) cm−1; 1H NMR (400 MHz, CDCl3): δ 2.17 (s, 3H, 
-CH3), 2.33 (s, 3H, -CH3), 2.53 (dd, J = 17.0, 2.0 Hz, 
1H, H-C-H of benzodiazepine), 2.78 (dd, J = 10.1,  
2.0 Hz, 1H, H-C-H of benzodiazepine), 3.92 (s, 1H,  
-CH of benzodiazepine), 5.89 (s, 1H, -NH of 
benzodiazepine), 6.90-7.68 (m, 17H, Ar-H), 8.45  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.4 (2), 39.3, 63.1, 113.4, 114.5, 119.7 (2), 
121.6, 125.6, 126.4, 126.5, 128.2, 128.7 (2), 129.2, 
129.6 (2), 129.8 (2), 130.3, 130.5, 131.7, 136.2, 
137.4, 137.9, 139.8, 145.2, 150.1, 162.8; LC-MS: m/z 
468.20 [M+]. Anal. Calcd for: C32H28N4: C, 82.02; H, 
6.02; N, 11.96. Found: C, 82.01; H, 6.03; N, 11.97%. 
Physical constants and characterization of 2-(2-
chlorophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-
4-yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2m: 
IR (KBr): 692 (-C-H bending, aromatic ring), 714 (-
C-Cl stretching, -Cl group), 742, 762 (-C-H bending, 
1,2-substituted ring (benzodiazepine)), 819 (-C-H 
bending, 1,4-substituted benzene ring), 969 (-C-H 
bending, aromatic ring), 1306 (-C-N stretching, 
pyrazole ring (>N-H)), 1369 (-C-H bending, -CH3 
group), 1452 (-C-H bending, aromatic ring), 1537, 
1570 (-N-H bending, benzodiazepine ring (>N-H)) 
cm−1; 1H NMR (400 MHz, CDCl3): δ 2.37 (s, 3H,  
-CH3), 2.50 (dd, J = 8.5, 5.3 Hz, 1H, H-C-H of 
benzodiazepine), 2.74 (dd, J = 5.4, 1.8 Hz, 1H, H-C-H 
of benzodiazepine), 3.92 (s, 1H, -CH of 
benzodiazepine), 5.84 (s, 1H, -NH of 
benzodiazepine), 6.85-7.64 (m, 17H, Ar-H), 8.42  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.2, 38.6, 57.8, 113.3, 114.5, 119.6 (2), 
121.8, 126.4, 126.7, 126.9, 127.9, 128.1, 128.2, 128.5 
(2), 128.7, 129.7 (2), 129.8 (2), 130.2, 130.5, 131.7, 
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132.4, 137.4, 140.1, 143.3, 145.4, 150.1, 162.6; LC-
MS: m/z 488.20 [M+]. Anal. Calcd for: C31H25ClN4: 
C, 76.14; H, 5.15; N, 11.46. Found: C, 76.15; H, 5.18; 
N, 11.45%. 
Physical constants and characterization of 2-(4-
chlorophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-
4-yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2n: 
IR (KBr): 698 (-C-H bending, aromatic ring), 743, 
757 (-C-H bending, 1,2-substituted ring 
(benzodiazepine)), 778 (-C-Cl stretching, -Cl group), 
816 (-C-H bending, 1,4-substituted benzene ring), 972 
(-C-H bending, aromatic ring), 1319 (-C-N stretching, 
pyrazole ring (>N-H)), 1378 (-C-H bending, -CH3 
group), 1475 (-C-H bending, aromatic ring), 1551, 
1579 (-N-H bending, benzodiazepine ring (>N-H)) 
cm−1; 1H NMR (400 MHz, CDCl3): δ 2.32 (s, 3H,  
-CH3), 2.52 (dd, J = 9.8, 1.6 Hz, 1H, H-C-H of 
benzodiazepine), 2.76 (dd, J = 8.7, 5.3 Hz, 1H, H-C-H 
of benzodiazepine), 3.88 (s, 1H, -CH of 
benzodiazepine), 5.90 (s, 1H, -NH of 
benzodiazepine), 6.87-7.65 (m, 17H, Ar-H), 8.45 (s, 
1H, -CH of pyrazole); 13C NMR (100 MHz, CDCl3):  
δ 21.0, 39.3, 63.2, 112.8, 114.6, 119.8 (2), 121.6, 
123.5 (2), 126.4, 126.8, 128.5, 128.7 (2), 128.9 (2), 
129.8 (2), 129.5 (2), 130.2, 130.4, 131.9, 132.4, 
137.6, 138.8, 139.9, 145.2, 150.1, 162.6; LC-MS: m/z 
488.15 [M+]. Anal. Calcd for: C31H25ClN4: C, 76.14; 
H, 5.15; N, 11.46. Found: C, 76.15; H, 5.17; N, 
11.44%. 
Physical constants and characterization of 2-(4-
fluorophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-
yl)-2,3-dihydro-1H-benzo[b][1,4]diazepine, 2o: IR 
(KBr): 683 (-C-H bending, aromatic ring), 747, 750  
(-C-H bending, 1,2-substituted ring (benzodiazepine)), 
827 (-C-H bending, 1,4-substituted benzene ring), 975 
(-C-H bending, aromatic ring), 1017 (-C-F stretching,  
-F group), 1328 (-C-N stretching, pyrazole ring (>N-
H)), 1358 (-C-H bending, -CH3 group), 1451 (-C-H 
bending, aromatic ring), 1536, 1578 (-N-H bending, 
benzodiazepine ring (>N-H)) cm−1; 1H NMR (400 
MHz, CDCl3): δ 2.35 (s, 3H, -CH3), 2.56 (dd, J = 16.8, 
8.2 Hz, 1H, H-C-H of benzodiazepine), 2.77 (dd,  
J = 5.4, 1.7 Hz, 1H, H-C-H of benzodiazepine), 3.91  
(s, 1H, -CH of benzodiazepine), 5.89 (s, 1H, -NH of 
benzodiazepine), 6.85-7.64 (m, 17H, Ar-H), 8.43  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.4, 39.0, 63.3, 113.3, 114.5, 115.4 (2), 
119.8 (2), 121.6, 126.3, 126.6, 128.4, 128.5 (2), 128.7 
(2), 129.4 (2), 129.5 (2), 130.2, 130.7, 131.8, 136.4, 
137.4, 139.8, 145.1, 150.4, 160.7, 162.5; LC-MS: m/z 
472.23 [M+]. Anal. Calcd for: C31H25FN4: C, 78.79; H, 
5.33; N, 11.86. Found: C, 78.80; H, 5.35; N, 11.84%. 
Physical constants and characterization of 2-
(2,4-difluorophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2p: IR (KBr): 685 (-C-H 
bending, aromatic ring), 742, 758 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 815 (-C-H 
bending, 1,4-substituted benzene ring), 967 (-C-H 
bending, aromatic ring), 1104 (-C-F stretching, -F 
group), 1323 (-C-N stretching, pyrazole ring (>N-H)), 
1394 (-C-H bending, -CH3 group), 1484 (-C-H 
bending, aromatic ring), 1517, 1576 (-N-H bending, 
benzodiazepine ring (>N-H)) cm−1; 1H NMR  
(400 MHz, CDCl3): δ 2.35 (s, 3H, -CH3), 2.55 (dd,  
J = 10.0, 1.5 Hz, 1H, H-C-H of benzodiazepine),  
2.76 (dd, J = 5.9, 1.7 Hz, 1H, H-C-H of 
benzodiazepine), 3.90 (s, 1H, -CH of 
benzodiazepine), 5.84 (s, 1H, -NH of 
benzodiazepine), 6.69-7.62 (m, 16H, Ar-H), 8.45  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.4, 39.2, 56.3, 104.2, 104.6, 110.7, 113.2, 
114.7, 120.1 (2), 121.7, 126.3, 126.7, 128.2, 128.5 
(2), 129.4 (2), 129.7 (2), 129.9, 130.2, 130.5, 131.8, 
137.4, 139.5, 145.2, 150.2, 159.3, 161.1, 162.7;  
LC-MS: m/z 490.22 [M+]. Anal. Calcd for: 
C31H24F2N4: C, 75.90; H, 4.93; N, 11.42. Found:  
C, 75.92; H, 4.92; N, 11.42%. 
Physical constants and characterization of 2-
(2,4-dichlorophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-benzo[b][1,4] 
diazepine, 2q: IR (KBr): 686 (-C-H bending, 
aromatic ring), 731 (-C-Cl stretching), 744 (-C-H 
bending, 1,2-substituted ring (benzodiazepine)),  
821 (-C-H bending, 1,4-substituted benzene ring), 956  
(-C-H bending, aromatic ring), 1276 (-C-N stretching, 
pyrazole ring (>N-H)), 1409 (-C-H bending, -CH3 
group), 1452 (-C-H bending, aromatic ring), 1504, 
1587 (-N-H bending, benzodiazepine ring (>N-H)) 
cm−1; 1H NMR (400 MHz, CDCl3): δ 2.33 (s, 3H,  
-CH3), 2.52 (dd, J = 5.3, 1.8 Hz, 1H, H-C-H of 
benzodiazepine), 2.76 (dd, J = 5.4, 2.9 Hz, 1H, H-C-H 
of benzodiazepine), 3.93 (s, 1H, -CH of 
benzodiazepine), 5.86 (s, 1H, -NH of 
benzodiazepine), 6.84-7.66 (m, 16H, Ar-H), 8.45  
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.1, 38.4, 57.8, 113.2, 114.7, 119.6, 119.8 
(2), 121.7, 126.3, 126.6, 126.9, 128.1, 128.5 (2), 
129.4 (2), 129.7 (2), 130.1, 130.4, 131.2, 133.8, 
137.4, 139.9, 141.4, 145.2, 150.6, 151.3, 162.8; LC-
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MS: m/z 522.15 [M+]. Anal. Calcd for: C31H24Cl2N4: 
C, 71.13; H, 4.62; N, 10.70. Found: C, 71.15; H, 4.63; 
N, 10.72%. 
Physical constants and characterization of 2-
(3,4-dichlorophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2r: IR (KBr): 690 (-C-H 
bending, aromatic ring), 727 (-C-Cl stretching), 741, 
759 (-C-H bending, 1,2-substituted ring 
(benzodiazepine)), 824 (-C-H bending, 1,4-substituted 
benzene ring), 974 (-C-H bending, aromatic ring), 
1312 (-C-N stretching, pyrazole ring (>N-H)), 1377  
(-C-H bending, -CH3 group), 1473 (-C-H bending, 
aromatic ring), 1531, 1565 (-N-H bending, 
benzodiazepine ring (>N-H)) cm−1; 1H NMR  
(400 MHz, CDCl3): δ 2.34 (s, 3H, -CH3), 2.54 (dd,  
J = 8.7, 3.6 Hz, 1H, H-C-H of benzodiazepine), 2.77 
(dd, J = 9.3, 5.5 Hz, 1H, H-C-H of benzodiazepine), 
3.89 (s, 1H, -CH of benzodiazepine), 5.91 (s, 1H, -NH 
of benzodiazepine), 6.82-7.64 (m, 16H, Ar-H), 8.46 
(s, 1H, -CH of pyrazole); 13C NMR (100 MHz, 
CDCl3): δ 21.4, 39.2, 62.7, 113.3, 114.7, 120.0 (2), 
121.8, 125.4, 126.3, 126.7, 128.2, 128.4, 128.6 (2), 
129.4 (2), 129.7 (2), 130.2 (2), 130.5, 131.6, 131.8, 
131.9, 137.1, 139.4, 143.2, 145.3, 150.2, 162.5;  
LC-MS: m/z 522.12 [M+]. Anal. Calcd for: 
C31H24Cl2N4: C, 71.13; H, 4.62; N, 10.70. Found: C, 
71.12; H, 4.65; N, 10.69%. 
Physical constants and characterization of 2-(2-
bromo,4-chlorophenyl)-4-(1-phenyl-3-(p-tolyl)-1H-
pyrazol-4-yl)-2,3-dihydro-1H-
benzo[b][1,4]diazepine, 2s: IR (KBr): 513 (-C-Br 
stretching, -Br group), 682 (-C-H bending, aromatic 
ring), 719 (-C-Cl stretching), 740, 756 (-C-H bending, 
1,2-substituted ring (benzodiazepine)), 818 (-C-H 
bending, 1,4-substituted benzene ring), 965 (-C-H 
bending, aromatic ring), 1342 (-C-N stretching, 
pyrazole ring (>N-H)), 1386 (-C-H bending, -CH3 
group), 1482 (-C-H bending, aromatic ring), 1520, 
1573 (-N-H bending, benzodiazepine ring (>N-H)) 
cm−1; 1H NMR (400 MHz, CDCl3): δ 2.32 (s, 3H,  
-CH3), 2.52 (dd, J = 9.3, 5.5 Hz, 1H, H-C-H of 
benzodiazepine), 2.78 (dd, J = 5.7, 2.1 Hz, 1H, H-C-H 
of benzodiazepine), 3.92 (s, 1H, -CH of 
benzodiazepine), 5.89 (s, 1H, -NH of 
benzodiazepine), 6.87-7.68 (m, 16H, Ar-H), 8.43 (s, 
1H, -CH of pyrazole); 13C NMR (100 MHz, CDCl3): δ 
21.0, 38.4, 59.3, 113.1, 114.9, 120.1 (2), 121.7, 123.4, 
126.5, 126.8, 128.1, 128.3 (2), 129.5 (2), 129.6 (2), 
129.9, 130.2, 130.4, 130.7, 131.8, 133.0, 137.4, 139.5, 
143.7, 145.2, 150.6, 162.7; LC-MS: m/z 566.11 [M+]. 
Anal. Calcd for: C31H24BrClN4: C, 65.56; H, 4.26; N, 
9.87. Found: C, 65.55; H, 4.27; N, 9.86%. 
Physical constants and characterization of 2-
methoxy-4-(4-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-
yl)-2,3-dihydro-1H-benzo[b][1,4]diazepin-2-
yl)phenol, 2t: IR (KBr): 688 (-C-H bending, 
aromatic ring), 744, 754 (-C-H bending, 1,2-
substituted ring (benzodiazepine)), 821 (-C-H 
bending, 1,4-substituted benzene ring), 950 (-C-H 
bending, aromatic ring), 1060, 1220 (-C-O-C 
stretching, -OCH3 group), 1276 (-C-N stretching, 
pyrazole ring (>N-H)), 1386 (-C-O-H bending, -OH 
group), 1409 (-C-H bending, -CH3 group), 1456 (-C-
H bending, aromatic ring), 1506, 1589 (-N-H 
bending, benzodiazepine ring (>N-H)) cm−1; 
1H NMR (400 MHz, CDCl3): δ 2.34 (s, 3H, -CH3), 
2.53 (dd, J = 7.2, 6.0 Hz, 1H, H-C-H of 
benzodiazepine), 2.75 (dd, J = 8.8, 3.4 Hz, 1H, H-C-H 
of benzodiazepine), 3.74 (s, 3H, -OCH3), 3.90 (s, 
1H, -CH of benzodiazepine), 5.87 (s, 1H, -NH of 
benzodiazepine), 6.70-7.67 (m, 16H, Ar-H), 8.47  
(s, 1H, -CH of pyrazole), 9.98 (s, 1H, -OH); 
13C NMR (100 MHz, CDCl3): δ 21.2, 38.7, 56.4, 
63.5, 110.3, 113.4, 114.7, 115.2, 119.2, 119.7 (2), 
121.7, 126.3, 126.8, 128.2, 128.5 (2), 129.4 (2), 
129.8 (2), 130.1, 130.4, 131.5, 137.2, 139.9, 145.3, 
146.8, 147.5, 150.2, 162.7; LC-MS: m/z 500.23 
[M+]. Anal. Calcd for: C32H28N4O2: C, 76.78; H, 
5.64; N, 11.19. Found: C, 76.80; H, 5.66; N, 11.20%. 
 
Conclusion 
In conclusion, new hybrids of pyrazole and 
benzodiazepine have been synthesized and 
characterized by different spectral techniques.  
All newly synthesized compounds were evaluated  
for their antibacterial and antifungal activity  
against different strains of bacteria and fungi using 
serial dilution method. On the basis of above 
mentioned data of biological activity, it may be 
concluded that synthesized novel series of compounds 
exhibited good to excellent activity against different 
bacterial and fungal strains. Evaluation of compounds 
2j, 2m and 2q exhibited excellent activity against 
bacterial strains while compounds 2i, 2k, 2l and  
2t showed prominent activity against fungal  
strains. Results of biological activity conclude that 
electron withdrawing and electron donating groups 
were much effective for bacterial and fungal strains 
respectively. 
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